0000000000421179

AUTHOR

Franco De Conno

showing 3 related works from this author

Role of Octreotide, Scopolamine Butylbromide, and Hydration in Symptom Control of Patients with Inoperable Bowel Obstruction and Nasogastric Tubes

2000

Bowel obstruction may be an inoperable complication in patients with end-stage cancer. Scopolamine butylbromide (SB) and octreotide (OCT) have been successfully used with the aim of reducing gastrointestinal (GI) secretions to avoid placement of a nasogastric tube (NGT); however, there have been no comparative studies concerning the efficacy of these drugs. Furthermore, there is little information about the role played by parenteral hydration in symptom control of these patients. In a prospective trial that involved all 17 inoperable bowel-obstructed patients presenting to our services with a decompressive NGT, patients were randomized to OCT 0.3 mg/day or SB 60 mg/day for 3 days through a …

Gastrointestinal agentPalliative carebusiness.industryNauseaOctreotideAbdominal distensionmedicine.diseaselaw.inventionBowel obstructionAnesthesiology and Pain MedicineRandomized controlled triallawAnesthesiaMedicineNeurology (clinical)medicine.symptombusinessProspective cohort studyGeneral Nursingmedicine.drugJournal of Pain and Symptom Management
researchProduct

Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: A…

2000

Bowel obstruction may be an inoperable complication in patients with end-stage cancer. Scopolamine butylbromide (SB) and octreotide (OCT) have been successfully used with the aim of reducing gastrointestinal (GI) secretions to avoid placement of a nasogastric tube (NGT); however, there have been no comparative studies concerning the efficacy of these drugs. Furthermore, there is little information about the role played by parenteral hydration in symptom control of these patients. In a prospective trial that involved all 17 inoperable bowel-obstructed patients presenting to our services with a decompressive NGT, patients were randomized to OCT 0.3 mg/day or SB 60 mg/day for 3 days through a …

Anesthesiology and Pain MedicineScopolamine butylbromideHydrationNeurology (clinical)OctreotideNursing (all)2901 Nursing (miscellaneous)Bowel obstructionCancer
researchProduct

Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC

2012

Here we provide the updated version of the guidelines of the European Association for Palliative Care (EAPC) on the use of opioids for the treatment of cancer pain. The update was undertaken by the European Palliative Care Research Collaborative. Previous EAPC guidelines were reviewed and compared with other currently available guidelines, and consensus recommendations were created by formal international expert panel. The content of the guidelines was defined according to several topics, each of which was assigned to collaborators who developed systematic literature reviews with a common methodology. The recommendations were developed by a writing committee that combined the evidence deriv…

medicine.medical_specialtyEvidence-based practicePalliative careVomitingAlternative medicineMEDLINECentral Nervous System DiseasesNeoplasmsmedicineHumansRenal InsufficiencyGrading (education)business.industryPalliative CareChronic painmedicine.diseaseAnalgesics OpioidSystematic reviewOncologyEvidence-Based PracticeFamily medicineAnesthesiaNeuralgiaChronic PainbusinessCancer painConstipationThe Lancet Oncology
researchProduct